Overview and Scope
Anthracycline is a class of powerful chemotherapy drugs derived from certain types of Streptomyces bacteria. These drugs work by interfering with the DNA (deoxyribonucleic acid) of cancer cells, preventing their growth and replication and are used to treat various types of cancer, including breast cancer, lymphomas, leukemia and more.
Sizing and Forecast
The anthracycline market size has grown strongly in recent years. It will grow from $1.41 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of cancer, growing demand for personalized cancer treatment, rising awareness of the benefits of anthracyclines, investment in anthracycline .
The anthracycline market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing awareness about cancer treatment, investments in research and development for cancer treatments, growing demand for effective and convenient treatments for cancer, growing number of screening programs for cancer, government initiatives. Major trends in the forecast period include advancements in anthracycline formulations, combination therapies, cardioprotective strategies, developing biosimilars of anthracyclines.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report
Segmentation & Regional Insights
The anthracycline market covered in this report is segmented –
1) By Drugs: Daunorubicin; Doxorubicin; Epirubicin; Idarubicin; Mitoxantrone; Valrubicin
2) By Dosage: Powder; Capsule; Solution; Injection; Suspension; Other Dosages
3) By Application: Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Hodgkin’s Lymphoma; Non-Hodgkin’s Lymphoma; Bladder Cancer; Breast Cancer; Other Metastatic Cancers
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Asia-Pacific was the largest region in the anthracycline market in 2023. The regions covered in anthracycline market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12914&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer is expected to propel the growth of the anthracycline market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Anthracycline, a class of chemotherapy drugs, plays a significant role in cancer treatment as it prevents cell division by disrupting the structure of the DNA and terminating its function. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase from 1.8 million new cancer cases diagnosed in 2020. Further, around 609,820 cancer-related deaths are anticipated in 2023, with an expected 606,520 in 2020. Therefore, the increasing prevalence of cancer is driving the growth of the anthracycline market.
Key Industry Players
Major players in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.
The anthracycline market report table of contents includes:
1. Executive Summary
2.Anthracycline Market Characteristics
3.Anthracycline Market Trends And Strategies
4. Anthracycline Market analysis
5.Anthracycline Market Size And Growth
6.Anthracycline Segmentation
7.Anthracycline Regional And Country Analysis
.
.
.
27.Anthracycline Competitive Landscape And Company Profiles
28.Anthracycline Key Mergers And Acquisitions
29.Anthracycline Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Bristol-Myers Squibb Company
- Fresenius SE & Co. KGaA
- Merck & Co. Inc.
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
